Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
02:00pm, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
01:47pm, Tuesday, 01'st Apr 2025
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit – MRK
01:31pm, Tuesday, 01'st Apr 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
12:30pm, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
12:11pm, Tuesday, 01'st Apr 2025
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk,
Dogs Of The Dow Chase April's 'Safer' Buy
12:05pm, Tuesday, 01'st Apr 2025
Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs
Here is Why Everyone Should Own Schwab’s SCHD ETF
10:30am, Tuesday, 01'st Apr 2025
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The current market uncertainty has sparked investor inter
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co.
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
06:45am, Tuesday, 01'st Apr 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24.
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
05:45am, Tuesday, 01'st Apr 2025
NEW YORK , April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: Th
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
08:48pm, Monday, 31'st Mar 2025
SHANGHAI , March 31, 2025 /PRNewswire/ -- On April 1, 2025 , Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization optio
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc.(MRK)
06:30pm, Monday, 31'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
